Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Sep 22;7:12168. doi: 10.1038/s41598-017-12488-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

CD4+ T cells activated under the Th1 polarizing condition respond to rhIL-7 after transferring into CTX-conditioned tumor-bearing hosts. The schema outlines the timeline of experimental procedures. Balb/c mice were inoculated with A20HA tumors subcutaneously in one flank. When tumor sizes reach ~170 mm², mice were treated with CTX (150 mg/kg) followed by adoptive transfer of in vitro-differentiated HA-specific Th1 CD4 T cells (1 × 10⁶ Th1 cells/mouse). A cohort of mice were then subcutaneously injected rhIL-7 (10 ug/injection) at the indicated time points. (A) Phenotypic characterization of in vitro-cultured HA-specific Th1 CD4 T cells. Cytokine profile and Foxp3 level of the cultured Th1 cells were evaluated by FACS. Numbers indicate the percentage of cells positive for the assayed marker. (B) IL-7Rα expression on in vitro-cultured HA-specific Th1 CD4+ T cells before adoptive transfer. (C) rhIL-7 administration enhances the expansion and maintenance of the infused Th1 cells. Tail blood samples collected at the indicated time points were analyzed for donor Th1 cell frequencies by FACS. (D) rhIL-7 administration leads to accelerated complete tumor rejection. The numbers of day needed to achieve complete tumor rejection are plotted. Results are pooled from 2 independent experiments. ***P < 0.001.